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cPopulation-Based Study of Capsular Warning Syndrome and Progno-
sis After Early Recurrent TIA
Paul NN, Sinoni M, Schandratheva A, et al. Neurology 2012:79:1356-62.
Conclusions: Capsular warning syndrome comprises 1.5% of transient
ischemic attack (TIA) presentations but has a poor prognosis, with a 7-day
stroke risk of 60%. With the exception of capsular warning syndrome,
recurrent TIAs 7 days are not associated with a greater stroke risk than a
single TIA.
Summary: Stroke risk after TIA is highest within the first 7 days (Hill
MD et al, Neurology 2004;62:2015-20). In addition, many guidelines
recommend urgent evaluation for carotid stenosis for patients with more
than two TIAs 7 days (Johnston SC et al, Ann Neurology 2006;60:301-
13). Capsular warning syndrome, manifested by multiple stereotype motor
TIAs, is thought to place patients at particular risk and precedes capsular
infarction (Donnan GA et al, Neurology 1993;43:957-62). However, it is
unclear whether patients with multiple TIAs have relatively untreatable or
treatable underlying pathologic conditions such as carotid stenosis or atrial
fibrillation. The authors used data from the Oxford Vascular Study (OXVASC)
to delineate whether patients with multiple TIAs are at high early stroke risk
and whether a treatable underlying condition is more common in patients
with multiple TIAs. They studied clinical characteristics, acute STROKE
treatment (TOAST) classification, and risk of stroke in 1000 consecutive
patients with incident and recurrent TIAs as part of the prospective, popu-
lation-based Oxford Vascular Study. Of the 1000 patients with TIAs, 170
had a further TIA 7 days (105 24 hours). Multiple TIAs were not
associated with carotid stenosis or atrial fibrillation.Much of the 10.6% (95%
confidence interval [CI], 6.5%-15.9%) risk of stroke in the first 7 days after
the an initial TIA was due to patients with small-vessel disease (SVD)
etiology (10 of 24 vs 8 of 146; odds ratio, 12.3; 95% confidence interval,
3.7-41.9; P .0001), particularly in those withmotor weakness (ie, capsular
warning syndrome) compared with hemisensory events (9 of 15 [60%], 95%
CI, 35.3-84.7 vs 1 of 9 [11.1%], 95% CI, 0-31.7; P  .03). The 7-day risk
of stroke after recurrent TIA was similar to the risk after a single TIA in
patients with non-SVD TIA (8 of 146 [5.5%] vs 76 of 830 [9.2%]; odds
ratio, 0.58; 95% CI, 0.25-1.3; P  .20). All of the nine patients with stroke
after a capsular warning syndrome had recurrent TIA 24 hours after the
first TIA, and the subsequent stroke occurred72 hours of the second TIA
in eight patients. The ABCDE2 scores of all preceding TIAs were 4 in all
nine patients with capsular warning syndrome before their stroke.
Comment: The data point out that not all TIAs have the same
prognosis for stroke. In particular, multiple TIAs without association with
large-vessel disease may have the worst prognosis of all. The implication is
that the emphasis on recurrent TIAs in many societal guidelines scores may
not be justified. At least in this study, multiple TIAs were not associated with
medically (atrial fibulation) or surgical (cervical carotid stenosis) correctable
conditions. Patients with capsular warning syndrome should have treatment
emphasis on hydration, antiplatelet, and anticoagulation therapies and,
perhaps, thrombolysis rather than a search for an underlying surgically
correctable large-vessel problem.
Clinical Outcomes Using a Platelet Function-Guided Approach for
Secondary Prevention in Patients With Ischemic Stroke or Transient
Ischemic Attack
Depta JP, Fowler J, Novak E, et al. Stroke 2012;43:2376-81.
Conclusion: Modification of antiplatelet therapy based on platelet
function testing after ischemic stroke or a transient ischemic attack (TIA)
results in higher rates of adverse clinical outcomes.
Summary: Failure to respond to aspirin in patients with ischemic stroke
is associated with an increased risk of cardiac events and death as well as
decreased functional status (Ozben S et al, J Neurol 2011;258:1979-89).
There are also adverse cardiac events associated with clopidogrel nonre-
sponse. However, improvement in clinical outcomes by intensifying anti-
platelet therapy has not been demonstrated in patients with ischemic stroke
or TIA. The authors sought to determine clinical efficacy and safety of
platelet function-guided modification of antiplatelet therapy in patients with
ischemic stroke or TIA. From January 2005 to August 2007, 324 patients
with ischemic stroke underwent platelet function testing using platelet
aggregometry. A mean platelet aggregation20% with 0.5 mg/mL arachi-
donic acid or 70% with 5 mmol/L adenosine diphosphate, or both, was
defined as aspirin nonresponse. Clopidogrel nonresponse was defined as a
mean platelet aggregation40% with 5 m/L adenosine diphosphate. Any
increase in platelet therapy occurring after testing was considered a modifi-
cation of antiplatelet therapy. Clinical outcomes were then compared be-
i
w
282ween patients with and without platelet function-guided modification of
ntiplatelet therapy using univariate and propensity score-adjusted analysis.
n patients with ischemic stroke or TIA, 128 (43%) and 54 (35%) were
onresponders to aspirin and clopidogrel, respectively. After platelet func-
ion testing, antiplatelet therapy was increased in 73 patients (23%). After
ropensity score matching, with 61 in each group, antiplatelet therapy
odification was associated with significantly increased rates of death and
schemic events (hazard risk, 2.24; 95% confidence interval; 1.12-4.47; P 
02) compared with no modification of antiplatelet therapy. There was also
trend toward increased bleeding (hazard risk, 3.56; 95% confidence
nterval, 0.98-12.9; P  .05).
Comment: The study found that increasing antiplatelet therapy in
atients using aspirin or clopidogrel, or both, based on platelet function
esting was not associated with better clinical outcomes and might be
ssociated with higher adverse events. Why this is so is unclear. It is known
hat clinical factors that predict antiplatelet nonresponses are not consistent
etween different platelet function tests (Seok JI et al, Clin Neurol Neuro-
urg 2008;110:110-6). In addition, the increased risk associated with non-
esponse to antiplatelet agents may reflect increased patient morbidity rather
han modifiable risk factors. Current guidelines do not recommend platelet
unction testing for management of ischemic stroke or TIA (Furie KL,
troke 2011;42:227-76). The data here suggest no changes are currently
eeded in these guidelines with respect to antiplatelet function testing.
ombined Proximal Stent Grafting Plus Distal BareMetal Stenting for
anagement of Aortic Dissection: Superior To Standard Endovascular
epair?
offerberth SC, Newcomb AE, Yii MY, et al. J Thorac Cardiovasc Surg
012;144:956-62.
Conclusion: Combined proximal descending aortic endografting plus
istal bare-metal stenting for aortic dissection may decrease late distal aortic
omplications compared with conventional endovascular repair.
Summary: Stent grafts have been described in conjunction with open
urgical techniques to decrease distal aortic complications in patients with
ype A aortic dissection. In such cases, stent grafts appear to help decompress
he false lumen, with resulting thrombosis and remodeling. However, after
uccessful thoracic stent graft placement for aortic dissection, distal thora-
oabdominal aortic segments often remained dissected, with the abdominal
orta failing to remodel in 50% to 80% of cases (Eggebrecht H et al, Eur
eart J 2006;27:489-98). This can result in malperfusion or aneurysm
egeneration with rupture, or both. The combination of descending aortic
ndografting plus distal bare-metal stenting to manage aortic dissection has
een termed the STABLE technique (Staged Total Aortic and Branch
esseL Endovascular reconstruction). In the current study, the authors
ompared the outcomes of standard proximal descending aortic stenting for
ortic dissection vs STABLE in treating type A and type B thoracic aortic
issection. From January 2003 to December 2010, 63 patients underwent
ndovascular treatment for acute aortic dissection (type A, n  24; type B,
 21) or chronic type B dissection (n  18). Of these patients, 40
nderwent proximal descending aortic endografting plus distal bare-metal
tenting (group 1), and 23 underwent proximal descending stent graft repair
lone (group 2). All patients with type A dissection underwent open surgical
ntervention plus adjunctive retrograde endovascular repair. Patents were
omparable for baseline characteristics and treatment indications, but there
ere more active smokers (P  .03) in the STABLE group. Intraoperative
haracteristics were also similar, but four patients in group 2 developed
alperfusion syndrome postoperatively (P  .02). Hospital mortality was
%. At a mean follow-up of 49 months, nine patients (43%) in group 2
equired an unplanned secondary intervention compared with four patients
11%) in group 1 (P  .007). Reinterventions for thoracoabdominal aortic
neurysm or distal ischemia were performed in four patients (19%), with two
f these being from group 2 (P  .03). Late aortic-related deaths occurred
n one (5%) and two (5%) patients in groups 1 and 2 respectively.
Comment: In this study, the STABLE cohort appeared to achieve
reater rates of complete false lumen thrombosis. However, most still
xhibited persistent patent false lumens, and both treatment approaches in
ost cases failed to achieve complete false lumen thrombosis of the abdom-
nal aorta. Potential advantages of the STABLE technique with respect to
linically relevant end points of aortic-related death and need for future
nterventions on the distal dissected aorta need to be evaluated with a
ell-performed randomized trial.
